Niki BioSolutions, Inc. (NASDAQ:NIKI) ("Niki BioSolutions" or the "Company"), a clinical-stage life sciences company focused on developing advanced genomic and biomarker testing solutions, today announced that its wholly owned subsidiary, DiamiR Biosciences Corp. ("DiamiR"), will be presenting a poster at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) conference on Wednesday, November 19th, in Boston, MA.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.